Ontology highlight
ABSTRACT: Introduction
Amyloid-related imaging abnormalities (ARIA) are a common, dose-dependent effect of amyloid-targeting antibodies, strongly associated with the apolipoprotein E (APOE) ?4 allele.Methods
We describe the clinical course and management of a 66-year-old white male (APOE ?4/?4) enrolled in an observational study that included amyloid and tau positron emission tomography (PET), who received aducanumab through the ENGAGE clinical trial.Results
Acute symptoms included headache and encephalopathy, and magnetic resonance imaging revealed ARIA-E and ARIA-H. Malignant hypertension and epileptiform activity were treated with nicardipine and levetiracetam. Subsequent clinical/imaging worsening prompted a course of methylprednisolone. Symptoms and ARIA-E resolved over 6 months, while ARIA-H persisted. Quantitative analysis of interval amyloid PET showed reduced signal in pre-existing areas but increased signal posteriorly; while tau PET showed increased signal overall.Discussion
In an APOE ?4/?4 patient, ARIA symptoms were accompanied by malignant hypertension and epileptiform activity, and pulsed steroids reversed edema. Studies from larger cohorts may clarify the optimal treatment and pathophysiology of ARIA.
SUBMITTER: VandeVrede L
PROVIDER: S-EPMC7545921 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
VandeVrede Lawren L Gibbs Daniel M DM Koestler Mary M La Joie Renaud R Ljubenkov Peter A PA Provost Karine K Soleimani-Meigooni David D Strom Amelia A Tsoy Elena E Rabinovici Gil D GD Boxer Adam L AL
Alzheimer's & dementia (Amsterdam, Netherlands) 20201009 1
<h4>Introduction</h4>Amyloid-related imaging abnormalities (ARIA) are a common, dose-dependent effect of amyloid-targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.<h4>Methods</h4>We describe the clinical course and management of a 66-year-old white male (APOE ε4/ε4) enrolled in an observational study that included amyloid and tau positron emission tomography (PET), who received aducanumab through the ENGAGE clinical trial.<h4>Results</h4>Acute symptoms included ...[more]